To study the existence of different mutations in acute intermittent porphyria, erythrocyte porphobilinogen deaminase activity and enzyme protein concentration were investigated in 125 porphyria gene carriers from 31 families, and in 121 apparently healthy controls. Porphobilinogen deaminase concentration g/gHb) was quantified using a recently developed double-sandwich ELISA. The ratio of enzyme catalytic activity to the concentration of enzyme protein was expressed s the porphobilinogen specific activity (nkat/g). The controls had a mean porphobilinogen deaminase concentration of 160 ± 35 μg/gHb and a specific activity of 762 ±127 nkat/g. Two different types of mutation causing acute intermittent porphyria were detected. The majority (91%) of gene carriers, from 25 families, had a diminished porphobilinogen deaminase concentration of 102 ± 18 μg/gHb, with a slightly lowered specific activity of 634 ±105 nkat/g. In 9% of the gene carriers, representing six different families, an increase in porphobilinogen deaminase concentration to 269 ± 46 μg/gHb, and a highly significant reduction in specific activity to 234 ± 48 nkat/g, were found, which indicates the presence of a different mutation.
Introduction
have a reduced activity of porphobilinogen Acute intennittent porphyria is a dominantly inher-deaminase 1 ). Measurement of the erythrocyte activity ited (1) inborn error of haem biosynthesis characte-of the enzyme has proved to be a valuable tool in the rized by abdominal and neuropsychiatric Symptoms detection of latent carriers of the disease. However, (2, 3) . The gene carrier state is pften asymptomatic. there exists an overlap zone of enzyme activity, where Certain drugs, hormones, steroids, infections and star-both acute intermittent porphyria gene carriers and vation may precipitate acute attacks of the disease. non-carriers are found (4) (5) (6) (7) (8) (9) . Hepatic 5^-aminolaevulinic acid synthase activity is u u i j . j , ,
. The porphobilinogen deaminase gene has been cloned induced and an mcreased unnary excretion of 5-ami-/4 ΛΧ f , 7 Λ Γ ' *. /^ <~>\ ,. -.. j , ,·ι· rr * 0°) and shown to code for two enzymes (11, 12) . nolaevulinic acid and porphobilinogen occur. Meter-X r /a , "" ΛΛΛ \ -r Λ ^ · ^ -*u • --*· Λ * * One form (Μ τ 42000) is found exclusively m erythoozygotes for the acute intermittent porphyria gene . j «. Λ Λ · /Λ ^>ΙΛΛΛ\ · r r poietic tissue, and an extended Version (Af r 44000) is present in non-erythropoietic cells. The cloned gene this approach has been of diagnostic value. Porphobilinogen deaminase has been purified and monospecific polyclonal anitbodies against the enzyme have been produced in rabbits (15) (16) (17) (18) (19) . Different classes of enzyme defect have been identified from the amount of immunologically cross-reacting enzyme material (CRIM) in erythrocyte lysates of acute intermittent porphyria heterozygotes. Four classes of mutation were identified with the use of rocket immunoelectrophoresis (15) (16) (17) , two CRIM-negative and two CRIM-positive. The majority of CRIMnegative families, designated type l, exhibited halfnormal porphobilinogen deaminase activity, which was accounted for by a reduction of porphobilinogen deaminase protein. Some families had a normal erythrocyte enzyme activity (20) and were designated CRIM-negative type 2. Other families had CRIMpositive mutations. One type had moderately elevated concentrations of porphobilinogen deaminase protein in erythrocyte lysate and was designated CRIM-positive type l. The other CRIM-positive mutation, type 2, had markedly more enzyme protein.
In the present study a Swedish collective of acute intermittent porphyria heterozygotes and normal controls was investigated for erythrocyte porphobilinogen deaminase activity, porphobilinogen deaminase protein concentration measured by ELISA (21) and porphobilinogen deaminase specific activity, i.e. enzyme activity related to the concentration of enzyme protein.
Materials, Methods and Human Subjects

Materials
Microtitre plates and an Immunowash 8 were obtained from Nunc (Roskilde, Denmark). ELISA absorbances were read in a MR 700 Microplate reader, Dynatech Laboratories (Guerasey, Great Britain). Evacuated heparinized test tubes were purchased from Becton-Dickinson (Plymouth, Great Britain).
Porphobilinogen deaminase activity
The activity of porphobilinogen deaminase in erythrocyte lysate was measured according to the method of Magnussen et al. (22) . The enzyme activity was expressed in two ways: picokatal per gram haemoglobin (pkat/g Hb) and nanokatal per litre red blood cells (nkat/1). The latter method of calculation was employed in the original publication, and it is used again here to facilitate comparison with earlier reports and earlier investigations in our laboratory.
The ELISA A monospecific polyclonal antiserum was raised in rabbits against the erythropoietic form of porphobilinogen deaminase, purified from human red blood cells (23) . For immunological quantification of porphobilinogen deaminase enzyme protein in human erythrocyte lysate, a double-sandwich enzyme-linked immunosorbent assay (ELISA) was developed (21) . The IgG fraction used was shown to be monospecific by immunoblotting, rocket inununoelectrophoresis and immunotitratiön. A measuring ränge from 4 ng to 50 pg was demonstrated. Intraand inter-assay coefficients of Variation were 6% and 7% re^· spectively. Lysis of the erythrocytes was achieved by freezing at -20 °C and thawing. Prior to analysis, 25 of the lysate was diluted by adding 100 ml of 50 mmol/1 Tris-HCl pH 7.5, 0.15 mol/1 NaCl. One hundred of the l: 4000 dilution was added to each of the microtitre plate wells. Duplicate samples were used. Erythrocyte lysate from a patient with a high concentration of porphobilinogen deaminase, äs determined by titration against the purified enzyme, was used äs an internal Standard and included in each assay. Haemoglobin concentration was measured in the diluted erythrpcyte lysate samples in the MR 700 Microplate reader äs the absorbance at 410 nm. Assay results were expressed äs microgram porphobilinogen deaminase en·ẑ yme protein per gram haemoglobin ( ^/g Hb).
Specific activity
The porphobilinogen deaminase specific activity was deter= mined in erythrocyte lysates from controls and acute intermitt ent porphyria by dividing the porphobilinogen deaminase activity (pkat/g Hb) by the porphobilinogen deaminase protein concentration fag/g Hb) äs measured by ELISA. The specific activity was expressed äs nanokatal per gram porphobilinogen deaminase enzyme protein (nkat/g).
Human subjects
Carriers of the acute intermittent porphyria gene, 125 individuals from 31 different families, were investigated. According to geneajogical data, 68 of the carriers were descended from the large family frorn nprthern Sweden first described by Waiden·? ström (l, 24). The diagnosis of acute intermittent porphyria was documented by a careful investigation of biochemical find·î ngs, family history of acute intermittent porphyria and clinical Symptoms. Eighty nine of the 125 acute intermittent porphyria gene carriers were investigated for 5-aminolaevulinate and porphobilinogen in the urine. Excess excretion was found in 82 of them and in seven a normal amount of S-^aminolaevulinate and porphobilinogen was found. The other 36 acute intermittent porphyria gene carriers were diagnosed only by porphobilinogen deaminase activity. There was no statistically significant difference in porphobilinogen deaminase activity between these groups (unpaired t-test, p < 0.001). As controls, 121 äpparently healthy individuals of raatching age and sex were used.
Blood samples
Heparinized blood was collected by venous puncture and sent by post to the laboratory. After centrifugation at 2000 g for 10 minutes at room temperature, the plasma was carefully removed. The erythrocytes were stored at ^-20 °C up to six moiiths before assay. Storage within this period of tirae did not affect the assay results.
Results
Erythrocyte porphobilinogen deaminase activity (36 ± 8 nkat/1) for the controls and 65 ± 16 pkat/g Hb (20 ± 5 nkat/1) for the acute intermittent porphyria gene carriers. A considerable overlap in activity between controls and patients is noted, in agreement with previous reports (4) (5) (6) (7) (8) (9) . At the time of the investigation one of the acute intermittent porphyria heterozygotes had a metastatic carcinoma of the prostate and severe anaemia with a haemoglobin concentration of 70 g/l. This patient exhibited a substantially increased porphobilinogen deaminase activity of 189 pkat/g Hb (58 nkat/1), (tab. 1), which is more than + 3 SD outside the mean for the remaining patients in the group. Three years earlier, when the patient had a normal haemoglobin concentration, his erythrocyte porphobilinogen deaminase activity was 20 nkat/1.
Erythrocyte porphobilinogen deaminase enzyme protein concentration Figure 2 shows the porphobilinogen deaminase enzyme protein concentration in controls and acute intermittent porphyria heterozygotes. The controls had a porphobilinogen deaminase concentration of 160 + 35 μg/gHb. The acute intermittent porphyria heterozygotes feil into two distinct groups. More than 90% of the patients (n = 113) from 25 different families, exhibited a lower concentration (102 ± 18 μg/g Hb), compared with the controls, which indicates a CRIM-negative mutation. However, 12 acute intermittent porphyria heterozygotes (9%) from six different families, had a markedly raised concentration of277 ± 52 μg/g Hb, which signifies a CRIM-positive mutation.
Tab. 1. Erythrocyte porphobilinogen deaminase (PBGD) activity, enzyme protein concentration and specific activity in 121 controls and 125 acute intermittent porphyria heterozygotes.
Acute intermittent porphyria n = 195
Acute intermittent Acute intermittent porphyria porphyria CRIM negative, n = 113 CRIM positive, n = ll Erythrocyte porphobilinogen deaminase specific activity
The erythrocyte porphobilinogen deaminase specific activity for the controls was 762 ±127 nkat/g. A significantly lower figure of 634 ±105 nkat/g (unpaired t-test 5 p < 0.001) was obtained for the CRIMnegative acute intermittent porphyria heterozygotes. Sixty eight of the 113 acute intermittent porphyria heterozygotes were descended from one large Swedish family. They had the same distribution of values for porphobilinogen deaminase specific activity s the other individuals in the CRIM-negative group ( fig.  3 ). The CRIM-positive gene carriers, with raised porphobilinogen deaminase concentration, exhibited a highly significant reduction in specific activity to 234 ± 48 nkat/g (n = 11) (tab. 1). One patient with raised specific activity, a proband in a CRIM-positive family ( fig. 4 , marked by arrow), was excluded (see Discussion). The inheritance of a CRIM-positive mutation is demonstrated in figure 4 .
Discussion
An ELISA method for use in porphyria routine diagnostic work was developed previously (21) for quantit tion of porphobilinogen deaminase enzyme protein concentration in erythrocyte lysates. In the present work it was applied in the study of a pop lation of Swedish acute intermittent porphyria gene carriers. . Two classes of mutations were revealed, one CRIMnegative with a low concentration of porphobilinogen deaminase enzyme protein and one CRIM-positive with a high porphobilinogen deaminase concentration, compared with controls. The CRIM-positive carriers exhibited a highly significant reduction in porphobilinogen deaminase specific activity, which indicates that immunoreactive non-cat lytic enzyme protein encoded by the mutant allele was detected by the ELISA. The CRIM-positive carriers also had a considerable increase of catalytically inactive protein and are probably of a type similar to the CRIMpositive type 2 class, previously described (17) , which may be caused by a mutation in the structur l gene. However, the CRIM-negative acute intennittent porphyria heterozygotes also had a significantly lowered porphobilinogen deaminase specific activity, although not of the same magnitude s the CRIM-positive group. In a pure regulatory gene defect the mutant allele is not considered to producc an enzyme wilh diminished activity. The CRIM-negative mutation(s) may thus represent changes in the DNA, leading to altered enzyme stability, mRNA transcription or processing. In the CRIM-positive family presented in figure 4 , the inheritance of the Imitation was clearly demonstrated, s all gene carriers showed an increased porphobilinogen deaminase concentration. All carriers also showed a decreased porphobilinogen deaminase specific activity, except the proband with anaemia and metastatic cancer of the prostate, who feil more than + 3 SD outside the group in this respect. He h d a porphobilinogen deaminase concentration of the same magnitude s the other gene carriers in the family but considerably raised enzyme activity, which explairis the increase in porphobilinogen deaminase specific activity to 520 nkat/g. Statistically he was not representative f the CRIM-positive^ group. It has been reported that the porphobilinogen deaminase enzyme activity in red blood cells is also subject to regulation by factprs other than the major gene on chromosome 11 (25) . It has further been shown that porphobilinogen deaminase activity may be increased in haemolytic disorders, in liver cirrhosis and other liver affections and in malignancies (26) (27) (28) .
By measuring porphobilinogen deaminase protein concentration in addition to porphobilinogen deaminase activity, different mutations of acute intermittent porphyria can be distinguished. The Information gained may be of diagnostic value, since in CRIMpositive families the raised porphobilinogen deaminase enzyme protein concentration and the decreased porphobilinogen deaminase specific activity distinguish between carriers and non-carriers of the gene defect. In CRIM-negative mutations, the porphobilinogen deaminase enzyme protein quantification yields additional Information on the erythrocyte enzyme. The diagnostic potential of this Information will be further evaluated. However, the ELISA method now available is less time-consuming than the traditional enzyme activity assay. It therefore offers a new means of rapidly investigating a large number of samples from populations at risk for the disease.
